https://www.selleckchem.com/products/ly333531.html
weight (7 mg and 14 mg doses) versus weekly subcutaneous dulaglutide 0·75 mg by week 52. FUNDING Novo Nordisk. BACKGROUND Given the unique phenotype of type 2 diabetes in Japanese patients, novel therapies such as oral semaglutide require evaluation in this population. PIONEER 9 aimed to assess the dose-response of oral semaglutide and to compare the efficacy and safety of oral semaglutide with placebo and a subcutaneous GLP-1 receptor agonist in a Japanese population. METHODS PIONEER 9 was a 52-week, phase 2/3a, randomised, controlled
Like
Comment
Share
